Endocyte (ECYT) Posts Narrower-than-Expected Q4 Loss

Endocyte (NASDAQ: ECYT) reported Q4 EPS of ($0.19), $0.06 better than the analyst estimate of ($0.25).

The Company expects that its cash balance at the end of 2015 will exceed $155 million. Spending is expected to increase from the first half of 2015 to the second half as the trials for EC1456 and EC1169 are expanded once the maximum tolerated doses are determined.

For earnings history and earnings-related data on Endocyte (ECYT) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Acme United (ACU) Misses Q1 EPS by 20c
• Park National Corp. (PRK) Tops Q1 EPS by 36c